Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Behav Brain Res. 2013 May 16;250:222–229. doi: 10.1016/j.bbr.2013.05.011

Fig. 6.

Fig. 6

Treatment with BM-MNCs reduces neurologic deficit after pMCAO. ANOVA revealed a significant difference in neurologic function among untreated, vehicle-treated, microglia-treated, and BM-MNC-treated groups on days 1, 3, 7 and 14 after pMCAO (F value for tests of between-subject effect = 9.33, P < 0.001). Treatment with BM-MNCs significantly improved neurologic function on day 14 compared to that in untreated, vehicle-treated, and microglia-treated groups (n = 10 rats per group). *P < 0.05 vs. all other groups.